WHAT WE CAN DO TO OVERCOME CANCER

GLOBAL DEMOGRAPHICS AND ASIA
The population of Asia has exploded in recent years, currently accounting for approximately half of the world's population, a proportion that is expected to grow to 60% by 2030. Future population growth will be centered on the countries of India, China and the Association of Southeast Asian Nations (ASEAN), which, crucially, will be accompanied with the advance of aging societies in all of these countries. By 2100, it is anticipated that the global population above the age of 50 will have grown from 1.4 billion to 4 billion, most of whom will be in Asia. Japan is currently the country with the most advanced aging society, but aging in countries like South Korea and China will accelerate over time and eventually surpass the aging society of Japan.
Viewed from a medical perspective the issue of aging is one that transforms disease structures, led by increased prevalence of cancer, and also causes medical costs to soar. The medical costs for Japan's over-65 population now accounts for one-third of all medical expenditure.
UNMET MEDICAL NEEDS IN ASIA AND THE WORLD
Global medical challenges can be broadly divided into three groups: (i) neglected tropical diseases (NTDs), (ii) noncommunicable diseases (NCDs) and (iii) rare and intractable diseases.
Approximately 1 billion people are affected by NTDs worldwide, predominantly in poor countries, and they have a tremendous impact on labor productivity and education opportunities in Africa and Asia, where .530 000 people succumb to such diseases each year. However, given the severity of their impact the World Health Organization (WHO) and G8 have to date taken the lead in energetically implementing campaigns to eliminate NTDs, and the effects of such campaigns are now starting to be seen in reduced incidence and morbidity rates of certain diseases and the provision of pharmaceutical products. NCDs is the collective name given to diseases that are not infectious, such as cardiovascular disease, diabetes, chronic obstructive pulmonary disease (COPD) and cancer, and according to the WHO (2008) , of the 57 million people who die around the world each year, 60%, or 36 million, die from an NCD. Due to the effects of globalization, including westernization of diets, reductions in exercise and the impact of smoking, these NCDs are already the largest cause of death in low and middle income countries. Given that in such countries the health insurance systems are underdeveloped or not established, NCDs are continuing to increase and in the future are expected to become a greater challenge than for developed countries.
There are said to be between 6000 and 7000 rare and intractable diseases, which affect 55 million people in North America and Europe alone. Although the number of sufferers of each individual disease and disorder may be small, the overall impact of rare and intractable diseases is something that can in no way be overlooked. At times, given that only a few patients may suffer from a rare disorder, this makes it difficult to advance methods diagnosis and development of new drugs, thus further exacerbating the problem.
As can be appreciated from the above, although undeniably great strides have been made in medicine and medical treatment, there are nonetheless a tremendous number of unmet medical needs still existing in the world. Taking a look at statistics shows that every year 7 million people succumb to cancer and 17 million die from circulatory disorders. Alzheimer's affects 24 million people worldwide and it is estimated that 350 million people are afflicted by diabetes. Approximately 7 million people are infected by tuberculosis, with 300 million suffering from asthma and 200 million from COPD.
CANCER IN ASIA
Now let us take a look at epidemiological data for cancer in Asia.
The most prevalent forms of cancer around the world by region are as follows. For men in Europe and North America the most common cancer is prostate cancer and for men in Asia it is lung cancer, with the exception of Japan, where it is gastric cancer. For women however, with the exception of China, India and parts of Africa, the most common cancer worldwide is breast cancer. For a number of types of cancer Japan shows similarities with Europe and North America in terms of frequency. The most representative of such cases is bowel cancer, which affects both men and women, and lung cancer in the case of men. However, it is also the case that Japan shows an intermediate frequency for some cancers, lying between the frequency of the West and that of Asian countries. For example, although the frequency of prostate cancer and breast cancer is not as high as in Western countries, it is higher than in Asian countries. This phenomenon suggests a correlation with the degree to which the living environment in Japan has undergone a process of Westernization. On the other hand, Japan still shares commonalities with the Asian region for certain types of cancer that have a high frequency in Asia, such as gastric cancer and liver cancer (particularly in women).
For these reasons, when considering cancer in Asia, it is necessary to look at cancer from two perspectives: cancer that reflects the globalization of dietary habits and living environments and cancer that is specific to the Asian region. This can be seen as something that needs to be given full consideration when engaging in research and development and marketing strategies for anti-cancer drugs. (Fig. 1) 
ASIA STRATEGY OF GLOBAL CORPORATIONS
The current global market for pharmaceutical products is broadly split into developing countries and emerging countries, the aspects of which are significantly different. Emerging countries, including the BRICs (Brazil, Russia, India, China), now provide the base for growth in the global drug market. It is said that from 2009 to 2014, 70% of the US$18.5 billion growth in the drugs market will be accounted for by emerging markets. In particular, annual growth of between 12 and 15% is anticipated in China, India and Russia in particular. However, on the other hand, in Europe and North America there is a great deal of pressure on reimbursement through insurance and pricing of drugs, as can be seen from issues such as the 50 million people who are said to have no medical insurance in the USA, and the policies in Europe to restrict medical expenditure, particularly drug expenditure, due to economic woes. Accordingly, a dramatic switch to Jpn J Clin Oncol 2014;44(Supplement 1) i49 generic drugs is occurring, which is keeping the growth rate of these established drug markets languishing in single figures.
It is against such a backdrop that global megapharmaceuticals have sought to grasp business opportunities in emerging countries. For example, in the case of Astra Zeneca, efforts are being made to achieve a target of 25% of all sales being made in emerging markets. As well as further developing established business in markets that are demonstrating tremendous growth in emerging countries like China and Russia, efforts are also being made to expand business in low income countries, where it is thought there is growth potential. Attempts are being made to ensure that such strategies not only match the situation in each individual market, but also make business sense. For example, generic drugs are still being used in far greater quantities in emerging countries than in developed countries. Companies are therefore seeking to boost the power of their brand and trust in their brand generics and enter markets and develop their business by selling these brand generics at a price that is competitive with very cheaply available commodity generic drugs. Furthermore, as can be seen in China, where over the course of five years there has been an increase of 200 million people who are covered by the medical insurance system, markets are continuing to develop at high speed. This is why not only AstraZeneca, but all other global mega-pharmaceuticals are concentrating their efforts in emerging economies. Almost all pharmaceutical companies have now established drug discovery and research laboratories in China. This is the direct opposite of the situation in Japan. (Fig. 2) In Japan it was once the case that the drug lag presented severe issues, whereby new drugs being used in other locations around the world could not be used in Japan. Drugs that had undergone clinical testing and approval in North America and Europe had to be submitted for the same clinical trials in Japan, with Japanese patients. The drug lag became a severe social issue and in response the regulatory authorities relaxed rules and regulations. The drug manufacturers have also cooperated in efforts to acquire data for Japanese patients almost in parallel with clinical trials in other countries, resulting in the drug lag issue being gradually diminished. In the future, by actively implementing further clinical trials with Asian people, including Japanese, the drug lag issue can expect to be further resolved. In addition, such further trials would create an enhanced database for Asian people, which would have merits for Asia as a whole as it would contribute to the development of outstanding new drugs for cancers that are particularly prevalent in Asia, as noted above.
ASIAN BUSINESS ENVIRONMENT
Drugs companies face environments and customers that present hurdles to developing business in Asia. In order to develop and expand markets in Asia and maximize benefits for the people of Asia, it is extremely important for the following issues to be resolved.
(1) LACK OF CONSIDERATION FOR INTELLECTUAL PROPERTY
There are cases in emerging countries where consideration for intellectual property is extremely lacking. For example, India has introduced a system, known as compulsory licensing, that forces pharmaceutical companies to give permission to generic manufacturers to sell drugs for which there is a strong need, even if the patents for such drugs are still valid. The cost of the generic drugs is about one-tenth of the cost of the original patented drugs and this deals a very strong blow to the companies that developed the drug. On the other hand, from the perspective of the Indian government, which seeks to raise the standards of medical care for its 1.2 billion people while being obliged to control surging medical costs, this What we can do to overcome cancer compulsory licensing system is a means of protecting the national interest.
(2) SIGNIFICANT HURDLES IN DEVELOPING NEW DRUGS
This issue is one that is not limited to Asia, it is one that impacts research and development-oriented drugs companies globally. It is said that in order to create one new drug requires investment of between 150 and 180 billion yen and a period of .10 years. It is currently the case that from 20 -30 000 candidate compounds only one new drug will ultimately be developed. It is only the drugs companies that are capable of investing such vast sums of money over a long period. National governments and universities do not possess the capacity to manage drug discovery and development through all aspects of the development process. Unless companies can sell their new drugs and make a profit and then invest these profits in further research and development it would be impossible to maintain the cycle of development and to discover new drugs. From this perspective the issue described in (1) above is also a significant one that is not limited to the medical issues faced by single countries.
(3) CONFRONTING INTERNATIONAL BUSINESS CUSTOMS
Among the various business customs around the world the one that presents particular issues is that of compliance. In many countries the payment for drugs is at least partially funded by government funds. The profits of drug companies are therefore received from taxpayers and from state social security expenses. Accordingly, it is absolutely imperative to maintain full transparency and for companies to impose strict discipline themselves. It goes without saying that acts of bribery are unconscionable, but so too should other acts be severely restricted, including those that seek to induce physicians to write prescriptions as well as false advertising of unconfirmed drug efficacy. In the USA the Department of Justice monitors such acts and has wide ranging powers of enforcement. These powers include the imposition of massive fines for companies found to be engaging in inappropriate acts, including those committed overseas and not just in the USA. The Department of Justice also has powers to formulate very strict improvement programs and implement monitoring and surveillance (CIA). However, due to differences in culture relating to compliance in certain regions of Asia it is regrettably not easy to ensure compliance with standards comparable to Western countries. Against the backdrop of ever-advancing globalization of markets the failure to engage adequately in compliance-related activities has the potential to severely impact the business activities and management of companies in some countries and regions.
(4) TOLERATION OF COUNTERFEIT DRUGS
Today, 10% of all drugs distributed around the world are thought to be counterfeit. These counterfeit drugs cause severe situations, where patients lose their lives or disorders cannot be cured. The WHO has issued warnings on this issue, but the reality is that counterfeit technologies are becoming ever-more advanced and even drug company experts cannot tell the difference between real and counterfeit drugs without opening a capsule and examining the contents. The investment effect of counterfeit drugs is larger than that of other illicit activities (narcotics, fake credit cards, counterfeit money, etc.). It is said that counterfeit drug production is particularly active in China and India.
PROGRESS IN DRUG DEVELOPMENT AS THE MISSION OF PHARMACEUTICAL COMPANIES: ADVANCES AND LIMITATIONS
Following advancement in science and technology, knowledge and methods of drug discovery have developed at a remarkable pace. Thanks to progress in combinatory chemistry the synthetic efficiency of compounds has risen 800-fold, and genetic analysis of DNA is now 1 billion times faster than it was when genetic analysis first began. What is more, the efficiency of structural analysis of proteins, which are one of the targets for drugs, has increased 1000-fold.
Furthermore, achievements have been made in the understanding about the onset of lung cancer. Initially understanding was based on histopathological classifications, but since the discovery of Epidermal Growth Factor Receptor (EGFR) and subsequently the discovery of many other causative genes, drug development has progressed to the point where it is possible to develop drugs to treat specific types of cancer.
Additionally, the emergence and development of bio-drugs has been astounding. From initial biological matter (e.g. growth hormone, interferon, interleukin, etc.), it is now possible to create antibody drugs and bio-drugs that have been artificially altered. Today, 350 million people around the world enjoy the benefits of bio-drugs.
Although it has been the case that there have been astonishing scientific advances in recent years, on the other hand, if we take a look at the big picture we see that for the last few decades the efficiency of drug discovery and development has been dropping (in terms of the number of drugs developed compared against cost). There is various debate concerning the development of new drugs, with some pointing out that development now focuses too much on minute details, which has resulted in soaring costs and a loss of focus on the need to ensure that drugs are effective in tackling human disorders. One of the problems is that knowledge and technology for predicting the effect of a newly developed drug on the human body are still underdeveloped and it is often still the case that it is impossible to make an ultimate decision on whether a new drug is actually going to be effective or not until after the final phase of clinical trials. Drugs created using iPS cells have the potential to overcome this challenge, and it is essential that academia, pharmaceuticals and governments work together to find a solution.
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PROSPECTS FOR FUTURE DEVELOPMENTS
The downturn in the efficiency of the development of new drugs is being treated as a serious issue in Europe and the USA. Although Japan has been lagging behind in a response to the problem, the importance of medical innovation has been noted and various moves have been witnessed. However, there are other moves being made in other countries, for example, the establishment of the Harmonization Center in Seoul, which was launched on the strong initiative of the South Korean government, seeking to integrate and unify regulations for drugs across the Asia-Pacific Economic Cooperation (APEC) region. Further commitment is required from the Japanese government. At the same time, Japanese pharmaceuticals are engaged in efforts seeking to strengthen cooperation with Asia, with a view to constructing a system for cooperation that would lead to the creation of new drugs originating in Asia. These developments will require further monitoring and are an encouraging sign.
From the perspective of cooperation between Asia and Japan, I believe there are a number of things that can be done in Asia to overcome cancer (Fig. 3) .
(1) The first thing is to know your enemy. This requires actions to deepen epidemiological understanding of cancer in Asia. It is perfectly reasonable to assume that a research consortium across the whole of Asia could be created, which would then engage in the promotion of research into types of cancer that are a common threat to Asia and work to understand the genetic background to such cancers. (2) The second thing is to improve access to drugs in Asia.
This would require the countries of Asia to integrate and unify their drugs-related regulations and application requirements to the greatest extent possible. It will also be important to consider the future establishment of an organization that could act as an 'Asian Drug Administration,' that would cover the whole of Asia. Japan should also participate actively in such an endeavor. (3) Of the utmost importance is to ensure that research and development and the business environment in Asia are of a global standard. For example, efforts should be made to resolve the question of how to reach a balance between the appropriate protection and utilization of intellectual property, which would help to promote and advance drug research and development and the pharmaceutical business in Asia as a whole.
DISCUSSION
(Responses made by Masuhiro Kato) Kato: It is drug discovery labs that have made moves into Asia, not clinical research bodies. By labs of individual companies making such moves the question is just how many outstanding researchers could be attracted to Japan. If Japan has truly outstanding research capacities, then even if the costs are a little more than other countries it can be expected that researchers will come to Japan. The issue is how to make the level of science in Japan appear appealing to the rest of the world.
The question of how much meaning there is to extend life by a further one year is one that is macro in nature. The introduction of innovative new drugs has the potential to contribute to a country's productivity and economy. In the United States there has been research performed that shows that the newer a drug is (the vintage), the more significant the length by which life can be extended. There is also research that shows that one dollar invested in the medical field has an investment effect of 36 dollars on society as a whole. What we can do to overcome cancer Kato: Medical expenses for the over-65 population account for one-third of total expenses in Japan. If a new treatment (drug, etc.) can be used to give such people an extra year of healthy, high-quality life there are significant merits for society. For example, it can be easily understood that the contribution that psychotropic drugs and anti-Alzheimer's drugs make could be significant in managing these conditions. If long life with good health can be broadly achieved at an appropriate cost it would have great merits for society.
